JGC
TEVA icon

J. Goldman & Co’s Teva Pharmaceuticals TEVA Stock Holding History

J. Goldman & Co’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-65,200
Closed -$1.32M – 737
2025
Q3 		$1.32M Buy
+65,200
New +$1.15M 0.03% 310

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

J. Goldman & Co's TEVA Position: Q3 2024 in Review

J. Goldman & Co sold out of Teva Pharmaceuticals (TEVA) in Q3 2024, closing a stake of 13,500 shares — an estimated $219K sold.

J. Goldman & Co first reported a position in TEVA in Q2 2015 and held it in 8 quarters. The position peaked at $18.7M in Q1 2016. 542 funds tracked by Wall St. Rank hold TEVA as of Q3 2024.

  • J. Goldman & Co reported no remaining Teva Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • J. Goldman & Co sold 13,500 Teva Pharmaceuticals shares in Q3 2024, an estimated $219K.
  • J. Goldman & Co first reported a position in Teva Pharmaceuticals in Q2 2015 and held it in 8 quarters.
  • J. Goldman & Co's Teva Pharmaceuticals position peaked at $18.7M in Q1 2016.
  • 542 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2024.

Based on J. Goldman & Co's 13F filing for Q3 2024, filed 14 Nov 2024.